Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

被引：0

作者：

Kavgaci, Akif ^{[1
]}

Kula, Serdar ^{[1
]}

Incedere, Fatma ^{[1
]}

Terlemez, Semiha ^{[1
]}

Tunaoglu, Fatma Sedef ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Cardiol, Ankara, Turkiye

来源：

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2023年 / 31卷 / 01期

关键词：

Pulmonary arterial hypertension; subcutaneous; treprostinil;

D O I：

10.5606/tgkdc.dergisi.2023.23748

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.

引用

页码：145 / 148

页数：4

共 50 条

[41] Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertensionBridge-to-transplant or long-term treatment?
Ablonczy, Laszlo
Tordas, Daniel
Kis, Eva
Szatmari, Andras
PEDIATRIC TRANSPLANTATION, 2018, 22 (02)
[42] Combination of balloon pulmonary angioplasty and subcutaneous treprostinil for the treatment of chronic thromboembolic pulmonary hypertension
Gerges, Christian
Kopec, Grzegorz
Sadushi-Kolici, Roela
Skoro-Sajer, Nika
Gerges, Mario
Klepetko, Walter
Matsubara, Hiromi
Lang, Irene M.
WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 381 - 381
[43] Treprostinil Use For Pulmonary Hypertension In Congenital Diaphragmatic Hernia
Lawrence, K. M.
Holly, H. L.
Herkert, L.
Waqar, L. N.
Bodenstab, H. M.
Hanna, B.
Peranteau, W. H.
Rintoul, N. E.
Hopper, R. K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
[44] Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension
Lang, Irene
Gomez-Sanchez, Miguel
Kneussl, Meinhard
Naeije, Robert
Escribano, Pilar
Skoro-Sajer, Nika
Vachiery, Jean-Luc
CHEST, 2006, 129 (06) : 1636 - 1643
[45] Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
Raina, Amresh
Coons, James C.
Kanwar, Manreet
Murali, Srinivas
Sokos, George
Benza, Raymond L.
PULMONARY CIRCULATION, 2013, 3 (01) : 116 - 120
[46] Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
Laura Mori, Ana
Rodriguez, Andrea
Alberto Gagliardi, Juan
Stewart Harris, Alejandro
EUROPEAN HEART JOURNAL-CASE REPORTS, 2021, 5 (10)
[47] Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension
Harutyunova, Satenik
Benkamin, Nicola
Eichstaedt, Christina
Marra, Alberto Maria
Xanthouli, Panagiota
Egenlauf, Benjamin
Gruenig, Ekkehard
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[48] Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
Skoro-Sajer, Nika
Gerges, Christian
Balint, Olga Hajnalka
Kohalmi, Dora
Kaldararova, Monika
Simkova, Iveta
Jakowitsch, Johannes
Gabriel, Harald
Baumgartner, Helmut
Gerges, Mario
Sadushi-Kolici, Roela
Celermajer, David S.
Lang, Irene Marthe
HEART, 2018, 104 (14) : 1195 - 1199
[49] Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension
Skoro-Sajer, N
Harja, E
Bonderman, D
Rezaie-Majd, S
Machherndl, S
Kneussl, M
Lang, MI
EUROPEAN HEART JOURNAL, 2003, 24 : 483 - 483
[50] Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension
He, Yuan
Li, Qiangqiang
Zhang, Chen
Keller, Bradley B.
Gu, Hong
CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (04) : 613 - 621

← 1 2 3 4 5 →